Literature DB >> 19689294

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Ulf Petrausch1, Christian H Poehlein, Shawn M Jensen, Chris Twitty, James A Thompson, Ilka Assmann, Sachin Puri, Michael G LaCelle, Tarsem Moudgil, Levi Maston, Kevin Friedman, Sarah Church, Elisa Cardenas, Daniel P Haley, Edwin B Walker, Emmanuel Akporiaye, Andrew D Weinberg, Sidney Rosenheim, Todd S Crocenzi, Hong-Ming Hu, Brendan D Curti, Walter J Urba, Bernard A Fox.   

Abstract

Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689294      PMCID: PMC3110749          DOI: 10.2174/156652409788970670

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  124 in total

Review 1.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

2.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

3.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

4.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.

Authors:  Ilona Kryczek; Shuang Wei; Gefeng Zhu; Leann Myers; Peter Mottram; Pui Cheng; Lieping Chen; George Coukos; Weiping Zou
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  In vitro expansion of CD4+CD25highFOXP3+CD127low/- regulatory T cells from peripheral blood lymphocytes of healthy Mycobacterium tuberculosis-infected humans.

Authors:  Jean-Michel Hougardy; Virginie Verscheure; Camille Locht; Françoise Mascart
Journal:  Microbes Infect       Date:  2007-06-30       Impact factor: 2.700

6.  Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma.

Authors:  G R Blumenschein; G N Hortobagyi; S P Richman; J U Gutterman; C K Tashima; A U Buzdar; M A Burgess; R B Livingston; E M Hersh
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

7.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.

Authors:  Xuefang Cao; Sheng F Cai; Todd A Fehniger; Jiling Song; Lynne I Collins; David R Piwnica-Worms; Timothy J Ley
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

8.  4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells.

Authors:  Beom K Choi; Jun S Bae; Eun M Choi; Woo J Kang; Shimon Sakaguchi; Dass S Vinay; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2003-12-23       Impact factor: 4.962

9.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

Review 10.  Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells.

Authors:  P Lane
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  12 in total

1.  WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.

Authors:  Anri Saitoh; Miwako Narita; Norihiro Watanabe; Nozomi Tochiki; Akie Yamahira; Takeshi Nakamura; Masami Kaji; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2010-01-27       Impact factor: 3.064

2.  Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Rebecca Waitz; Marcella Fasso; James P Allison; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

Review 3.  Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.

Authors:  Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

4.  B cells inhibit the antitumor immunity against an established murine fibrosarcoma.

Authors:  Andrea Maglioco; Damián G Machuca; María Noel Badano; Paula Nannini; Gabriela V Camerano; Héctor Costa; Roberto Meiss; Raúl A Ruggiero; Mirta Giordano; Graciela I Dran
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

Review 5.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

Review 6.  Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy.

Authors:  Eugene V Barsov
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

7.  Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010.

Authors:  Gregory B Lesinski; William E Carson; Elizabeth A Repasky; Wei-zen Wei; Pawel Kalinski; Michael T Lotze; Carl H June; William Petros; Natarajan Muthusamy; Thomas Olencki
Journal:  J Immunother       Date:  2010-09       Impact factor: 4.456

8.  Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

Authors:  David M Lubaroff; Badrinath R Konety; Brian Link; Jack Gerstbrein; Tammy Madsen; Mary Shannon; Jeanne Howard; Jennifer Paisley; Diana Boeglin; Timothy L Ratliff; Richard D Williams
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

Review 9.  Therapeutic HPV DNA vaccines.

Authors:  Ken Lin; Elena Roosinovich; Barbara Ma; Chien-Fu Hung; T-C Wu
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

10.  Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

Authors:  Saskia J A M Santegoets; Eveline M Dijkgraaf; Alessandra Battaglia; Philipp Beckhove; Cedrik M Britten; Awen Gallimore; Andrew Godkin; Cecile Gouttefangeas; Tanja D de Gruijl; Hans J P M Koenen; Alexander Scheffold; Ethan M Shevach; Janet Staats; Kjetil Taskén; Theresa L Whiteside; Judith R Kroep; Marij J P Welters; Sjoerd H van der Burg
Journal:  Cancer Immunol Immunother       Date:  2015-06-28       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.